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Abstract
Background: The progression of liver disease in patients with chronic hepatitis C virus (HCV)
infection is influenced by host and viral factors. Distinct clinical outcomes in patients infected with
different HCV genotypes have been described in the literatute. However, the association between
specific HCV genotype and clinical outcome remains unclear. We set out to study the natural
history of HCV genotype 1 and 3 infections in Campinas, São Paulo state, Brazil, focusing on
epidemiological, clinical, biochemical, and histological characteristics.
Methods:  Patients with HCV infection referred for treatment between January 2003 and
December 2006 were included in this study. We collected epidemiological, clinical, and laboratorial
data using standard forms.
Results: A total of 283 patients were included; genotype 1 was idenfied in 163 (57.6%) patients,
genotype 3 in 112 (39.6%), genotype 2 in 7 (2.5%), and genotype 4 in 1 (0.35%). Patients with
genotype 2 and 4 were excluded from analysis. Multivariate analysis showed that intravenous
energetic drug, positive cryoglobulin, and cirrhosis were independently and significantly associated
with HCV genotype 3 (p < 0.05).
Conclusion: Genotype 3 currently seems to be associated with intravenous energetic drug, high
frequency of cryoglobulinemia, and advanced liver disease in our region. Understanding the
distribution of the different HCV genotypes can elucidate transmission of HCV and support optimal
prevention strategies.
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Background
Hepatitis C virus (HCV) infection affects approximately
170 million persons worldwide [1]. In some countries,
such as the United States and some in west Europe, HCV
is the main etiological factor of chronic hepatitis, end-
stage cirrhosis, and hepatocellular carcinoma (HCC)
[2,3]. The most common modes of HCV transmission is
through percutaneous exposure to contaminated blood,
transfusion of blood products before 1992, and intrave-
nous drug use. Other potential risk factors for hepatitis C
include intranasal use of cocaine, tattoing, body piercing,
accidental needle-stick injury, sexual contact, and perina-
tal exposure. In Brazil, HCV infection was also associated
with intravenous use of energetic drugs, such as Gluconer-
gan®, a non-illicit drug commonly used in the 1970s as a
stimulant [4,5].
The transmission of HCV is declining worldwide as a
result of the screening of blood products and implemen-
tation of standard precautions [1]. However, the fre-
quency of complications of HCV infection, including
hepatic decompensation and HCC, are increasing and are
expected to peak in 2015, because it can take several years
for HCV-infection to progress to liver disease [1].
HCV has a heterogeneous natural history. After acute
infection, 70% to 85% of patients develop chronic infec-
tion. Among those with chronic infection, 20% to 30%
develop progressive fibrosis, cirrhosis, and other compli-
cations, such as portal hypertension and HCC after an
average period of 20 years [6]. Conversely, chronic HCV
infection might not cause considerable severe complica-
tions. Host and viral factors probably influence liver dis-
ease progression [7].
Comparison of nucleotide sequence data led to the classi-
fication of HCV into six distinct major genotypes whose
genetic makeup differs by approximately 30% [8]. Geno-
type is closely associated with response to interferon
(IFN) and ribavirin (RBV) therapy, but its influence on the
course from HCV infection to liver disease remains
unknown [7,9].
The geographic distribution of HCV genotypes is mark-
edly heterogeneous throughout the world [10]. In addi-
tion, distinct epidemiological characteristic, clinical
presentation, and histological outcome of cases caused by
specific HCV genotypes have been described [11]. We
evaluated the natural history of HCV genotype 1 and 3
infections in Campinas, São Paulo state, Brazil.
Methods
We followed patients positive for HCV antibodies (Abbott
AxSYM® Anti-HCV 3.0, Abbott Laboratories, Wiesbaden,
Germany) and positive for HCV RNA (Amplicor HCV 2®,
Roche Diagnostics Systems Inc, Branchburg, USA) who
presented at the teaching Hospital of the Universidade
Estadual de Campinas, São Paulo state, Brazil from Janu-
ary 2003 through December 2006. This hospital is a
regional reference center for treatment of hepatic disease.
Patients already being treated with interferon or with con-
current infections caused by hepatitis B virus or HIV were
excluded from this study. Patients were followed for at
least six months after the completing hepatitis C treat-
ment.
We collected relevant information on standard forms.
Possible associations between HCV genotype and gender,
age, source of transmission, aminotransferase levels,
development of fibrosis, and cryoglobulinemia were
investigated. Cryoglobulinemia was evaluated by an in-
house method involving centrifugation and separation of
10 mL of serum and freezing at 0°C for seven days. All
tests and liver biopsies were done on samples drawn prior
to initiation of treatment.
We used amplicons generated by the Amplicor® HCV test
using a commercially available assay (Line Probe assay,
LIPA HCV, Innogenetics, Gent, Belgium) to identify HCV
genotype. This test is a reverse amplification assay based
on the hybridization of the amplified sequence from 5'-
nonconding region of HCV genome with oligonucleotide
probes immobilized as parallel lines on membrane strips.
The probes correspond to the sequence of the six most
common HCV genotypes and their subtypes.
The diagnosis of cirrhosis was based on clinical and labo-
ratory parameters (hyperbilirrubinemia, esophageal
varices, ascites, splenomegaly), or histological examina-
tion. Fibrosis stage was evaluated using METAVIR score,
where normal liver is designated as F0 and cirrhosis as F4
[12].
Patients with HCV genotype 1 infection received
pegylated interpheron (PEG-IFN) alfa-2a (180 μg) or 2b
(1.5 μg/Kg) subcutaneously once a week for 48 weeks,
while those with HCV genotype 3 received interpheron
alpha 3 MU subcutaneously three times a week for 24
weeks. All patients also received RBV, 1,000 mg to 1,250
mg, acording to patient's weight. Only data on patients
who completed the proposed treatment and follow up for
at least sixo months were included in the analysis. Sus-
tained virological response (SVR) was defined as negative
HCV RNA six months after the end of treatment.
Statistical analysis
We analyzed data using EPI-INFO version 5.00 (Centers
for Disease Control and Prevention, Atlanta, USA). P val-
ues less than 0.05 were considered statistically significant.
We used chi-square and Mann-Whitney statistical tests, asBMC Infectious Diseases 2008, 8:164 http://www.biomedcentral.com/1471-2334/8/164
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appropriate. Variables for which an association with HCV
genotype was suspected (i.e., p value = 0.20) were
included in a multivariate stepwise logistic regression
model to assess for confounding.
Results
A total of 283 patients were considered elegible for inclu-
sion in this study. Genotype 1 was detected in 163
(57.6%) patients, genotype 3 in 112 (39.6%), genotype 2
in 7 (2.5%), and genotype 4 in 1 (0.35%). Given the very
low frequency of genotypes 2 and 4, patients infected with
these genotype of HCV were excluded from analysis.
Two hundred one (73%) of the 275 patients included in
the study were men. The median age was 43 years (range:
17–69 years). There was no significant difference in gen-
der and age between patients with genotype 1 and 3 infec-
tions (Table 1). The most common risk factors for HCV
infection were blood transfusion before 1992 (present in
71 [25.8%] patients), intravenous energetic drug use
(Gluconergan®) (53 [19.3%]) and, intravenous illicit drug
use (44 [16.0%]). Eleven (4%) patients reported two risk
factors. Eighty-nine (32.4%) patients did not have any
HCV risk factor identified (Table 1). Blood transfusions
before 1992 was found with greater frequency in genotype
1 (28%) rather than genotype 3 (21.4%) infections, but
this difference was not statistically significant (p = 0.17).
Previous use of Gluconergan® was statistically significantly
associated with genotype 3 (p = 0.008) (Table 1). The
median alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were higher in genotype 3
than genotype 1 (p = 0.003 and p = 0.0001, respectively)
(Table 1). When we compared patients with and without
detectable serum cryoglobulins, we found that cryoglob-
ulinemia was more frequent among genotype 3-infected
patients rather than those infected with genotype 1 infec-
tion (p = 0.001) (Table 1).
Liver biopsies were perfomed on 241 (89%) of 275
patients. An additional 21 (8.1%) patients had clinical
signs and laboratory findings consistent with cirrhosis
and consequently a liver biopsy was not perfomed. Thus,
the analysis of stage of fibrosis was limited to 262 (95.3%)
patients. Thirty-eight (15.8%) of the 241 patients had his-
topathologically confirmed cirrhosis and 21 had clinical
cirrhosis (Table 2). Histologic findings of chronic hepati-
tis without cirrhosis were present in 203 (78.2%) patients.
Severe fibrosis (F3, F4, and clinical cirrhosis) was more
frequent among patients infected with genotype 3 (p =
0.0004) (Table 2). In addition, patients infected with gen-
otype 3 had cirrhosis significantly more often compared
with patients infected with genotype 1 (p = 0.001) (Table
2).
We initiated treatment of disease in 180 (65.4%) patients.
Among those, 39 (36.2%) of 97 patients with genotype 1
and 35 (45.5%) of 83 with genotype 3 achieved SVR. Mul-
tivariate stepwise logistic regression analysis showed that
clinical or histological cirrhosis (adjusted odds ratio [OR]
= 1.93, 95% confidence interval [CI] = 1.0–3.7), positive
cryoglobulin (adjusted OR = 1,96; 95% CI = 1.11–3.46),
and use of Gluconergan® (adjusted OR = 2,0; 95% CI =
1.03–4.09) were independently associated with HCV gen-
otype 3.
Discussion
HCV genotypes 1, 2, and 3 have a worldwide distribution
but their relative prevalence varies from one geographical
area to another. In North America and Europe, genotype
1 is responsible for over 70% of all HCV infections fol-
lowed by genotype 2 and then genotype 3 [9]. Genotype
Table 1: Patients characteristics associated with hepatitis C virus (HCV) genotypes 1 and 3 infections (n = 275).
Characteristic Genotype 1 (n = 163) Genotype 3 (n = 112) p value
n (%) n (%)
Male 114 (69.9) 87 (77.7) 0.15
Age (median range, yr) 43.0 (25–69) 42.5 (17–67) 0.70
Risk factor for HCV infection*
Intravenous energetic drug 23 (14.1) 30 (26.8) 0.008
Blood transfusion 47 (28.8) 24 (21.4) 0.17
Intravenous illicit drug use 22 (13.5) 22 (19.6) 0.17
Unknown risk 58 (34.5) 31(27.7) 0.16
Others** 18 (11.0) 11 (9.8) 0.75
ALT (median) 62.0 81.5 0.003
AST (median) 47.0 65.0 0.001
GT (median) 61.0 70.0 0.58
Positive cryoglobulin 88 (54.0) 80 (71.4) 0.001
*Eleven patients had two risk factors
** Others includes intranasal use of cocaine, tattoing, body piercing, accidental needle-stick injury
Reference ranges: ALT (alanine aminotransferase): 6–40 U/L; AST (aspartate aminotransferase): 6–40 U/L; 3/4GT (glutamyl transferase): 9–40 U/LBMC Infectious Diseases 2008, 8:164 http://www.biomedcentral.com/1471-2334/8/164
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4 is found almost exclusively in the Middle East and North
Africa, while genotypes 5 and 6 are common in South
Africa and Asia, respectively [9,13].
In agreement with previous studies in Brazil, we demon-
strated that HCV genotype 1 was the most prevalent gen-
otype, followed by genotypes 3 and 2 [4,14]. The
previously reported prevalence of genotype 3 among
patients with HCV infection in Brazil, around 30%, is
among the highest in the world [14]. In our study, which
was done among patients referred for treatment of hepatic
disease, we found an even higher genotype 3 prevalence,
40%.
An association between HCV genotypes and the mode of
HCV transmission has been reported by some authors in
certain areas of world [9,15]. In Europe, intravenous illicit
drug use is more common in patients with genotype 3
infection, while blood transfusion is commonly associ-
ated with genotype 1 [13]. However, in the United States,
some authors did not find an association between HCV
genotypes and modes of HCV transmission [9]. In our
study, blood transfusion prior to 1992 was the most fre-
quently reported risk factor for genotype 1 infection,
while the transmission of genotype 3 was associated with
intravenous energetic drug (Gluconergan ®) use. This find-
ing is in agreement with other studies in different regions
of Brazil [4,5]. Knowledge of the frequency and distribu-
tion of the HCV genotypes can provide information to
better understand the transmission of HCV and direct the
development of prevention strategies.
The association of HCV infection and cryoglobulinemia
has been previously reported and may be associated to the
virus' ability to infect mononuclear cells [16]. However,
the association between HCV genotype and cryoglob-
ulinemia remains unclear. Some studies have not found
an association between HCV genotype and cryoglobuline-
mia, while others have found higher frequencies of cry-
oglobulinemia among individuals infected with genotype
1 or 2 infections [17-19]. The association between cry-
oglobulins and a specific genotype varies from one region
to another and results from an interaction betwen viral
and host factors. The high frequency of cryoglobulins in
patients with genotype 3 infection observed in our study
could have resulted from hight frequency of cirrhosis
associated with this genotype, since crioglobulinemia
may represent a complication in patients with HCV infec-
tion, especially in those with cirrhosis [16,20].
The rate of progression of fibrosis varies markedly among
HCV-infected patients and the major factors known to be
associated with fibrosis progression are older age at the
time of infection, male gender, and excessive alcohol use
[7]. There is little evidence that viral factors, such as geno-
type, play a role in severity and outcome of liver disease.
In some studies from the United States and Europe, HCV
genotype 1 was found to be associated with a higher fre-
quency of cirrhosis [9,21]. However, many of these stud-
ies did not address possible confounding factors, such as
age and duration of infection. In studies that addressed
the confounding effect of these variables, the association
between genotype 1 and more severe liver disease was not
found [9,22].
We observed that patients infected with genotype 3 have a
higher frequency of cirrhosis, higher ALT and AST levels,
and the acquisition of HCV was related to intravenous
energetic drug. Quite possibly patients infected with gen-
otype 3 in our region may represent a sub population that
has characteristics associated with a more severe liver dis-
ease, such as consumption of alcohol or the longer length
of the infection. We were not able to analyze these factors
as part of this study.
Previous studies have shown that patients with genotype
1 infection treated with PEG-IFN alfa-2a or 2b plus RBV
achieved SVR rates of 42% to 46%; while patients with
genotype 3 infection treated with interferon alfa plus RBV
achieved SVR rates of 61% [22,23]. We found lower SVR
rates for genotype 1 and 3 infections (36.2% and 45.5%,
respectively) than these studies. A limitation of this study
is that dose reduction and race are important predictors
for SVR and we were unable to account for those. Further
studies are needed to confirm our findings and explore the
reasons for these different response rates, since this would
help design treatment plans for infected patients.
Table 2: Stage of fibrosis by Metavir system associated with HCV genotypes 1 and 3 in patients with chronic hepatitis C (n = 262).
Stage of fibrosis Genotype 1 (n = 154) Genotype 3 (n = 108)
n (%) n (%)
Mild or moderate 111 (72) 55 (51)
F0 4 (3) 0 (0.0)
F1 33 (21) 15 (14)
F2 74 (48) 40 (37)
Severe fibrosis 43 (28) 53 (49)
F3 19 (12) 18 (17)
F4 and clinical cirrhosis 24 (15.6) 35 (32.2)Publish with BioMed Central    and   every 
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Conclusion
In conclusion, genotype 1 was found to be the main gen-
otype in our study followed by genotype 3. Additionaly,
genotype 3 currently seems to be associated with intrave-
nous energetic drug, high frequency of cryoglobulinemia,
and advanced liver disease in our region. It is important to
consider and address these epidemiological and clinical
differences since chronic hepatitis is likely to an extra bur-
den to the healthcare system considering the cost and
social consequences associated with advanced liver dis-
ease.
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